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Abstract 
Haemolysis is a very common phenomenon and is referred as the release of intracellular 
components from red blood cells to the extracellular fluid. Haemolysed samples are often rejected 
in clinics due to the interference of haemoglobin and intracellular components in laboratory 
measurements. Plasma and serum based vibrational spectroscopy studies are extensively applied 
to generate spectral biomarkers for various diseases. However, no studies have reported the effect 
of haemolysis in blood based vibrational spectroscopy studies. This study was undertaken to 
evaluate the effect of haemolysis on infrared and Raman spectra of blood plasma. In this study, 
prostate cancer plasma samples (n=30) were divided into three groups (non-haemolysed, mildly 
haemolysed and moderately hemolysed) based on the degree of haemolysis and FTIR and Raman 
spectra were recorded using high throughput (HT)-FTIR and HT-Raman spectroscopy. 
Discrimination was observed between the infrared and Raman spectra of non-haemolysed and 
haemolysed plasma samples using principal component analysis. A classical least square fitting 
analysis showed differences in the weighing of pure components in non-haemolysed and 
haemolysed plasma samples. Therefore, it is worth to consider the changes in spectral features due 
to haemolysis when comparing the results within and between experiments. 
Keywords: Haemolysis, blood plasma, FTIR spectroscopy, Raman spectroscopy, principal 
component analysis, classical least squares fitting analysis. 
1. Introduction 
Haemolysis (or hemolysis) refers to the breakdown of erythrocytes and resulting in the release of 
intracellular components into the extracellular fluid, i.e. the plasma or serum [1] . Haemolysis is 
discernible as a red colouration of the plasma or serum after centrifugation of the sample and can 
occur both in-vivo and in vitro. The upper reference limit for free haemoglobin in plasma is around 
20 mg/L [2]. Several factors causing in-vitro haemolysis are given in Table 1 [2]. Not all 
haemolysed specimens can be associated with in-vitro haemolysis because more than 50 medical 
conditions are associated with in-vivo haemolysis [3], such as cancer [4], autoimmune disorders 
[5], surgery [6]  etc. In-vivo haemolysis can be easily concealed by in-vitro haemolysis. In these 
cases, samples haemolysed because of a medical condition may be refused because haemolysis 
had been attributed to improper specimen phlebotomy, without considering the condition causing 
in-vivo haemolysis [7]. 
In-vivo haemolysis can be distinguished from in-vitro haemolysis by estimating the concentration 
of haptoglobin [8]. Haptoglobin is formed in the liver and binds to free haemoglobin released from 
in-vivo lysed red cells to prevent its toxic effects [9]. The haptoglobin levels are reduced in the 
presence of large amounts of free haemoglobin, a decrease in the concentration of serum 
haptoglobin is the most marked laboratory indicator of in-vivo haemolysis [9]. In severe cases of 
in-vivo haemolysis, haptoglobin levels may be very low or even undetectable, whereas with in-
vitro haemolysis the concentration of haptoglobin is usually not affected [8]. However, several 
studies have examined the potential of haptoglobin as a marker of in-vivo haemolysis. Varying 
degrees of sensitivity and specificity for haptoglobin have been shown depending on the cutoff 
concentration used. One study used a haptoglobin cutoff of less than 25 mg/dL and demonstrated 
83% sensitivity and 96% specificity for intravascular haemolysis [10]. Another used a haptoglobin 
cutoff of less than 28 mg/dL and noted 91.8% sensitivity and 98.4% specificity for intravascular 
haemolysis [11]. On the other hand, decreased levels of haptoglobin can occur in the absence of 
haemolysis, due to the liver cirrhosis, disseminated ovarian carcinomatosis, pulmonary 
sarcoidosis, and elevated oestrogen states [9]. 
In general, there is no gold standard test to confirm in-vivo haemolysis, and most often labs rely 
on other clinical factors (e.g. increased reticulocyte count and decreased haptoglobin) and 
correlation with other laboratory markers (e.g., complete blood count, lactate dehydrogenase and 
indirect bilirubin) in addition to a patient’s history [2,9]. 
Many laboratory chemistry tests depend on the evaluation of light that passes through a sample, 
and therefore haemolysed blood can interfere with these tests, as the red colour of haemoglobin 
can interfere with the absorption of light as it passes through a haemolysed sample [12]. In 
spectrophotometric assays, the absorption peak of oxyhaemoglobin lies between 531 and 543 nm. 
This absorption peak is relatively broad so haemolysis intervenes over many wavelengths that are 
used for the quantification of analytes [12]. Haemolysis also interferes with laboratory tests by 
releasing analytes into the serum or plasma that are elevated in concentration within the red blood 
cells compared to serum or plasma, thereby giving false concentrations of measured analytes [13].  
The application of vibrational spectroscopy (infrared and Raman spectroscopy) to generate 
spectral biomarkers of disease using biofluids such as plasma or serum is gaining increased focus. 
Infrared spectroscopy is based on the absorption of infrared radiation by the sample under study 
and the fact that molecules absorb specific frequencies of the incident light which are characteristic 
of their structure. Raman spectroscopy is based on inelastic scattering of monochromatic light, 
usually from a laser source. Many articles have been published reporting the use of Fourier 
Transform Infrared (FTIR) and Raman spectroscopy with serum and/or plasma as non-invasive 
diagnostics for various diseases, including cancers [14–17]. Despite haemolysis being very 
common in practice, no spectroscopic study has examined its effects on spectral markers and the 
concentration of analytes.  
This study was undertaken to investigate the effect of haemolysis on Raman and FTIR spectra of 
plasma in prostate cancer patient plasma samples (n = 30). A combination of ultraviolet (UV)-
Visible, high throughput (HT) - Raman and HT-FTIR spectroscopies were used to evaluate the 
spectral content of both haemolysed and non-haemolysed plasma. Significant spectral differences 
were observed in the infrared and Raman spectra of non-haemolysed and haemolysed plasma 
samples. The acquired FTIR and Raman spectra were also analysed by principal component 
analysis (PCA) and classical least squares (CLS) fitting analysis in the MATLAB environment. 
The CLS fitting analysis was employed to estimate the changes in the weighting of various analytes 
in non-haemolysed and haemolysed plasma samples.  
2. Experimental section 
2.1. Ethical approval 
Ethical approval was awarded by the Technological University Dublin Research Ethics Committee 
for the collection of blood samples from healthy donors. The prostate cancer patients used in this 
study were recruited from the Cancer Trials Ireland (formerly All Ireland Cooperative Oncology 
Research Group, ICORG) trial 08−17 which is entitled “A Prospective Phase II Dose Escalation 
Study Using intensity modulated radiotherapy (IMRT) for High Risk N0 (cancer has not spread to 
nearby lymph nodes) M0 (or elsewhere in the body) Prostate Cancer (NCT00951535)”. The 
patients were recruited for a translational study on vibrational spectroscopy for monitoring 
radiation therapy response [18]. The translational research study was approved by the St Luke’s 
Radiation Oncology Network Research Ethics Committee and all research was performed in 
accordance with relevant guidelines and regulations. Informed consent was obtained from all 
participants. Fresh whole blood was drawn into Li-heparin tubes at St. Luke`s Radiation Oncology 
Network, St. Luke’s Hospital (SLRON SLH), in Dublin, and were coded before being transferred 
to the Technological University (TU) Dublin laboratory. Plasma from prostate cancer patients were 
used to study the effect of in-vivo haemolysis on Raman and FTIR spectra of blood plasma. The 
clinical characteristics of prostate cancer patients are detailed in Table 2. Plasma from male healthy 
donor (age, 50 years) was used to study the effect of in-vitro haemolysis on Raman spectra of 
blood plasma. 
2.2. Plasma isolation 
Plasma was isolated from these blood samples by centrifugation at 3500 g for 5 minutes at 180C. 
The samples were subsequently stored at -800C prior to FTIR and Raman acquisition. 
2.3. Haemoglobin isolation 
 
A volume of 1ml of whole blood sample was centrifuged at 3500 g for 5 minutes to remove plasma. 
The pelleted red blood cells (RBCs) was purified by washing with phosphate buffer saline (PBS)  
for at least three times. The residual PBS was removed by centrifugation at 3500 g for 1 minute . 
After purification, deionised water was added to the RBCs and sonication was performed for 30 
sec to rupture the RBCs. Then, the diluted haemoglobin was further centrifuged at 3500 g for 5 
minutes to remove RBC membrane. The isolated diluted hemoglobin sample was stored at -800C 
before Raman measurements.  
2.4. Ultraviolet - visible spectroscopy 
 
UV-visible spectroscopy is generally used in analytical chemistry for the quantitative 
determination of various analytes. UV-visible spectroscopy uses light in the visible and adjacent 
ranges. In this study, free haemoglobin of the plasma samples was measured 
spectrophotometrically (Perkin Elmer Lambda 900) with water as a blank. Thirty microliters of 
plasma samples were deposited on the quartz microsample cell with 0.1mm pathlength and the 
absorbance at 414 nm were used to determine the haemolysis in the sample. The concentration of 
haemoglobin in plasma was determined using the Beer-Lambert law.  
2.5. FTIR spectroscopy 
 
The sample preparation and acquisition methodology for FTIR spectra was detailed in our previous 
paper [18]. Briefly, plasma samples stored at -80° C were thawed at room temperature and were 
diluted threefold in physiological water. A volume of 4 μL diluted plasma sample was deposited 
on a 384-well silicon plate (Bruker Optics GmbH, Ettlingen, Germany), and air-dried at room 
temperature. For each sample, 10 spots were used giving 10 instrumental replicates. The plate was 
then inserted into a high-throughput module (HTS-XT, Bruker Optics GmbH) attached to an FTIR 
spectrometer (Tensor 27, Bruker Optics GmbH). FTIR spectra were acquired in the transmission 
mode using the OPUS v6.5 software (Bruker Optics GmbH) in the wavenumber range from 4000 
to 400 cm−1, using a spectral resolution of 4 cm−1 and 32 co-additions. FTIR spectra were then 
subjected to a quality test (OPUS v6.5) and details of this test are fully described in reference [19, 
20]. Spectra that passed the quality test were pre-processed and processed in the wavenumber 
range from 800 to 4000 cm−1. 
 
2.6. Raman spectroscopy 
 
Raman spectra from liquid plasma samples were recorded using an in house developed HT-Raman 
spectroscopy method [17]. Briefly, 20 µl of liquid plasma samples were deposited on a cover glass 
bottomed 96 well plate (MatTek corporation) and Raman spectra of the plasma samples were 
acquired using a 785nm laser focused through a 10x objective (N.A. 0.25). Spectra were recorded 
using a diffraction grating ruled with 300 lines/mm giving a spectral resolution of ~2.1cm-1. 
Spectra were recorded automatically from each well where the spectrometer was programmed 
using an in-house developed high throughput macro template. Each spectrum was acquired over 
the region from 400 –1800 cm-1. Ten spectra were recorded from each sample for each patient with 
a 20 s x 2 integration time. Multiple wavenumber calibration spectra of 1,4-Bis (2-methylstyryl) 
benzene and intensity calibration spectra of National Institute of Standards and Technology (NIST) 
Standard Reference Material (SRM) no. 2241 were recorded along with each sample acquisition 
and used in spectral post-processing. 
2.7. Pure molecular reference species recording 
All pure molecular references species (Table 3) were purchased from Sigma Aldrich. These 
molecular species include proteins, lipids and other analytes which are usually found in the blood 
plasma. Moreover, previous other studies also reported the variations in most of these molecular 
species due to the effect of haemolysis [13, 21–23].  Additionally, molecular reference species of 
lipids and fatty acids were included to study their interference in the plasma spectra due to in-vivo 
haemolysis. More details of these pure molecular reference species are provided in supplementary 
material. 
Approximately 1–2 mg of each lyophilised analyte or 10 µL of liquid analyte was deposited on a 
calcium fluoride slide and Raman spectra were recorded with a 785 nm laser excitation. The laser 
was focused through a 10× objective (N.A. 0.25) using a diffraction grating ruled with a grating 
of 300 lines per mm. Five spectra per sample were recorded for the acquisition time of 10 seconds 
and 2 accumulations. FTIR spectra of all analytes were recorded using Attenuated total reflectance 
(ATR)-FTIR (Perkin Elmer). Approximately 1 mg of lyophilised analyte or 5 µL of liquid analyte 
(allowed to dry at room temperature) was placed on the ATR crystal (Diamond / Zinc Selenide 
with refractive index 2.4) and FTIR spectra were acquired in the transmission mode using the 
spectrum software and using the following conditions: wavenumber range from 4000 to 700 cm−1, 
spectral resolution of 4 cm−1, and each spectrum was averaged over 8 scans. 
2.8. Data analysis 
All spectral processing procedures were carried out using MATLAB (R2017a; Mathworks Inc., 
Natick, MA), along with in-house developed algorithms and procedures available within the PLS 
Toolbox (v 8.0.2, Eigenvector Research Inc., Wenatchee, MA). 
2.8.1. Pre-processing 
Pre-processing of FTIR spectra includes baseline correction, calculation of second derivative 
spectra and vector normalisation. Baseline correction was performed using the rubberband 
baseline subtraction [24]. Second derivative spectra were calculated using Savitsky-Golay 
algorithm [25] and a window length of 9 points. All spectra were standardized using vector 
normalization before analysis. 
The acquired Raman spectra were wavenumber calibrated relative to an in-house standard of 1,4-
Bis (2-methylstyryl) benzene using in-house developed calibration procedures [26] and the 
instrument response correction was performed using the spectrum of NIST Standard Reference 
Material (SRM) no. 2241, according to the method described [27]. Briefly, SRM 2241 emits a 
broadband luminescence spectrum when illuminated with 785 nm Raman excitation laser. The 
shape of this luminescence spectrum is represented by a polynomial expression that relates the 
relative spectral intensity to the Raman shift. This polynomial along with a standard luminescence 
spectrum can be employed to determine the spectral intensity-response correction, which is unique 
to each Raman system. The derived instrument intensity response correction can be used to obtain 
Raman spectra that are corrected for instrument dependent artifacts [27]. The wavenumber and 
instrument response corrected Raman spectra were smoothed using a Savitzky-Golay filter. The 
background and baseline correction were performed using Extended Multiplicative Scattering 
Correction (EMSC). Then, spectra were standardized using vector normalization. An example of 
intensity corrected, and pre-processed liquid plasma spectrum is shown in Figure 1. 
2.8.2. Multivariate analysis 
Pre-processed FTIR and Raman spectra were further processed with PCA and CLS fitting analysis. 
2.8.2.1. PCA 
PCA was performed with the similar approach as described earlier [18].  In brief, PCA is a 
commonly used method for multivariate data compression and visualization. It describes data 
variance by identifying a new set of orthogonal features, called principal components (PCs).  
2.8.2.2. CLS fitting analysis 
In this study, classical least squares (CLS) fitting analysis was performed on the second derivative 
FTIR spectra and vector normalised Raman spectra to estimate the relative fraction (a proxy for 
concentration) of reference spectra (of pure components) within a sample spectrum. The use of 
CLS fitting analysis to determine the relative concentrations of cellular components have been 
reported previously [28,29]. The pure components used in this study are given in Table 2. CLS is 
an exploratory method that assumes that any complex spectrum is the linear sum of contributions 
from spectra of pure components that contribute to the spectrum as described in the following 
equation [30]: 
                                                  𝑆 =  𝑎!𝐶! + 𝑎"𝐶" +⋯+ 𝐸                                                                 
 Where S represents a sample spectrum, a1 and a2 are component spectra and C1 and C2 are the 
weights or concentrations assigned to each component spectrum. In the case of a Raman or FTIR 
spectrum, not all contributing pure components are known. Therefore, an error or residual, E, in 
the fitting estimation will be observed that will equate to the difference between the sample 
spectrum and the sum of the component spectra: 
                                                𝐸# = 𝑆# −  (𝑎!#𝐶! + 𝑎"#𝐶" + 𝑎$#𝐶$)                                                                    
Where E j is the error associated with the intensity of the j-th wavenumber. Applying CLS 
minimizes the error in fitting the sample spectrum, S. The minimum error occurs when the 
differential of the sum of squared errors is equal to zero.   







	= 0                                                         
Differentiating with respect to each of the component will give the above equation and using the 
method of simultaneous equations the weighting components can be calculated. Alternatively 
using matrix methods and the matrix of weighting coefficients can be solved for using the 
following equation. 
                                                    [𝐶] = 	 [𝐴]	[𝑎]0[𝑎𝑎0],!	                                                                                      
where a is a component of sample spectra. 
 
3. Results and discussion 
3.1. Haemoglobin spectra 
 
Three different types of  plasma samples were observed in our plasma biobank (Figure 2). The 
normal plasma sample is clear and pale yellow in colour (Figure 2C). The haemolysed plasma 
sample is pale red in colour (Figure 2A)  and the lipemic plasma sample is white in colour (Figure 
2B). Lipemia is a turbidity of the sample caused by aggregation of lipoprotein particles 31. 
Figure 3 shows a representative UV-Visible absorption spectrum of haemoglobin recorded from 
the haemolysed prostate cancer plasma sample. The absorption bands at 414 cm-1,  546 cm-1 and 
571 cm-1 indicates the presence of oxyhaemoglobin. Figure 4 shows the FTIR absorption spectrum 
recorded from the haemoglobin standard (Sigma Aldrich). As haemoglobin is a protein, the FTIR 
absorption spectrum contains amide I band (between 1600 and 1700 cm-1), amide II band (between 
1510 and 1580 cm-1), amide III band (between 1300 and 1400 cm-1), amide A band (between 3300 
and 3500 cm-1). Figure 5A, 5B and 5C shows the Raman spectra recorded from the lyophilised 
haemoglobin standard, diluted haemoglobin standard and the haemoglobin isolated from blood 
respectively. The Raman spectra acquired from the lyophilised haemoglobin standard gave a 
fluorescence signal because of the bright red colour of haemoglobin. However, the fluorescence 
signal was not observed in Raman spectra from diluted and isolated haemoglobin. This might be 
due to the reduction of red colour of haemoglobin by diluting with deionised water. The Raman 
spectrum from diluted haemoglobin and isolated haemoglobin contains protein related bands at 
750 cm-1, 1002 cm-1, 1035 cm-1, 1125-1150 cm-1, 1210 cm-1 (phenylalanine), 1170 cm-1 (tyrosine), 
1035 cm-1,  1230 cm-1 -1300 cm-1 (Amide III), 1480 cm-1 – 1580 cm-1 (Amide III),  and 1600 - 
1660 cm-1 (phenylalanine, tyrosine, Amide I).  These bands are more prominent in diluted 
haemoglobin compared to isolated haemoglobin from RBC. 
3.2. Plasma categorization based on haemolysis 
 
Specimens were categorized according to the haemoglobin concentration into three groups: 
• Group 1 (0 - 0.1g/L), non-haemolysed (n=12); 
• Group 2 (0.20 - 0.50 g/L), mildly haemolysed (n=10); 
• Group 3 (0.50 - 0.93 g/L), moderately haemolysed (n=8). 
 
The results were analysed to determine if non-haemolysed, mildly haemolysed and moderately 
haemolysed samples had a significant impact on the analyte concentrations estimated by CLS 
fitting analysis. The median free haemoglobin concentrations for groups 1, 2 and 3 were measured 
as 0.02, 0.44 and 0.71 g/L respectively. At free haemoglobin concentration of 0.2 g/L, haemolysis 
was visible by the light red colour of the plasma. The haemolysed plasma samples appeared to be 
more turbid compared to non-haemolysed plasma samples. The increase in turbidity in haemolysed 
samples may be due to hyperlipidemia. It has been reported that hyperlipidemia is associated with 
increased haemolysis [32]. It is postulated that enhanced lipid concentration changes the lipid 
content of the erythrocyte membrane, resulting in increased erythrocyte fragility and subsequent 
leakage of cellular content into the plasma [32].  
3.3. Comparison of spectral features of non-haemolysed and haemolysed plasma samples 
 
Figure 6 shows the mean FTIR spectra of non-haemolysed and haemolysed plasma obtained from 
the prostate cancer patients. To explain the differences between each group, difference spectra 
were computed by subtracting the spectra of haemolysed plasma samples from the spectra of non-
haemolysed plasma samples. The first panel in Figure 7 shows the difference FTIR spectra 
obtained from moderately haemolysed and mildly haemolysed plasma samples. The second panel 
shows the difference FTIR spectra obtained from mildly haemolysed and non-haemolysed plasma 
samples and the third panel shows the difference FTIR spectra obtained from moderately 
haemolysed and non-haemolysed plasma samples. 
Major differences were observed in the region around  1550 cm-1 (Amide II) [20] , 1660 cm-1 
(Amide I) [20], 1740-1760 cm-1 (stretching vibrations of (C=O) of fatty acids, triglycerides, and 
cholesterol esters) [33], 2800-2950 cm-1 (stretching vibrations of (CH2/CH3) of lipids fatty acids, 
triglycerides and proteins) [33], 3300 cm-1 (Amide A) [20]  and 3400-3600 cm-1 (OH stretch) [34] 
between non-haemolysed and haemolysed plasma groups. The increase in fatty acids (1740-1760 
cm-1), lipids (2800-2960 cm-1) and OH stretch (3400-3600 cm-1) and the decrease in glycogen, 
nucleic acids (1000-1100 cm-1) [33,35],  amide II (1550 cm-1), amide I (1660 cm-1) and amide A 
(3300 cm-1) were observed with an increase in haemolysis. The decrease in amide II, amide I and 
amide A suggests the decrease in protein content with an increase in haemolysis and the increase 
in fatty acids, lipids and OH stretch suggest the increase in lipids with an increase in haemolysis. 
The increase in lipids and fatty acids in haemolysed plasma samples may indicate in-vivo 
haemolysis [32]. As mentioned earlier, the haemolysed plasma specimens appeared to be more 
turbid compared to non-haemolysed plasma samples due to hyperlipidemia. The increase in lipid 
concentration with an increase in haemolysis has also been reported previously [32]. 
Figure 8 shows the mean Raman spectra of non-haemolysed and haemolysed plasma obtained 
from the prostate cancer patients. The first panel in Figure 9 shows the difference Raman spectra 
obtained from moderately haemolysed and mildly haemolysed plasma samples. The second panel 
shows the difference Raman spectra obtained from mildly haemolysed and non-haemolysed 
plasma samples and the third panel shows the difference Raman spectra obtained from moderately 
haemolysed and non-haemolysed plasma samples. Major intensity related differences were 
observed in the region around 877 cm−1, 881 cm−1, 1006 cm−1, 1085 cm−1, 1210 cm−1, 1270 cm−1, 
1302 cm−1, 1345 cm−1, 1450 cm−1, 1528 cm−1, and 1660 cm−1. The bands corresponding to 
phenylalanine (1006 cm−1 and 1210 cm−1) [36] increased with increase in haemolysis. The increase 
in the amide linkage bands (1302, 1340 cm−1) [37] was observed in non-haemolysed plasma 
compared to haemolysed plasma. The CH2 deformation (1340 cm−1) [37] bands were decreased 
with increase in haemolysis. The bands corresponding to cholesterol (881cm−1 and 1450 cm−1) [38] 
and triglycerides (877 cm−1, 1270 cm−1 and 1450 cm−1) [38] were increased with increase in 
haemolysis. This increase in lipid profile with an increase in haemolysis was also observed in the 
FTIR spectral analysis. 
 
3.4. Multivariate analysis 
3.4.1. PCA  
 
PCA was performed on second derivative of the mean FTIR spectra by patient, using the 
wavenumber range of 4000-800 cm-1. PCA was carried out with 10 PCs and the first 2 PCs 
accounted for ∼91% of the total percentage variance. The first two PCs were used to visualize the 
classification between the groups. The scatter plot revealed three well differentiated clusters 
between the analysed groups (Figure 10A). 
The PCA analysis showed clear discrimination between the FTIR spectra of non, mildly and 
moderately haemolysed plasma samples. PC1 showed the discrimination between the FTIR spectra 
of non and mild haemolysed plasma samples and moderate haemolysed plasma samples. PC1 
shows positive band associated with proteins (1657 cm-1) in the moderately haemolysed plasma 
group and negative bands associated with glycogen, nucleic acids (1040 cm-1, 1063 cm-1, 1090 cm-
1 and 1120 cm-1), lipids, triglycerides and fatty acids (1744 cm-1, 2853 cm-1, 2926 cm-1 and 2963 
cm-1) in the non and mildly haemolysed plasma groups. PC2 showed the discrimination between 
the FTIR spectra of non-haemolysed and mild haemolysed plasma samples. PC2 shows positive 
bands at 1040 cm-1, 1120 cm-1 and 1640 cm-1 in the mildly haemolysed plasma group and negative 
bands at 1744 cm-1, 2853 cm-1, 2926 cm-1 and 2963 cm-1 in the non-haemolysed plasma group. 
The positive bands in PC2 are assigned to glycogen, RNA and protein and negative bands are 
assigned to lipids, triglycerides and fatty acids.  The PCA analysis showed the main discriminating 
features between non-haemolysed and haemolysed plasma samples are related to glycogen, nucleic 
acids, proteins, fatty acids, triglycerides and lipids. The FTIR difference spectrum analysis also 
showed similar discriminating spectral features between the non-haemolysed, mild and moderate 
haemolysed plasma samples. 
Figure 11 shows the results of PCA analysis performed on the vector normalised Raman spectra 
of non-haemolysed and haemolysed plasma groups. The first two PCs accounted for ∼58% of the 
total percentage variance and the scatter plot revealed overlapped clusters between the analysed 
groups. Only PC1 showed the discrimination between the Raman spectra of non and mild 
haemolysed plasma samples and moderate haemolysed plasma samples. PC1 has positive bands 
at 1003 cm-1, 1080 cm-1, 1155 cm-1, 1430 cm-1 and 1650 cm-1 in the non and mildly haemolysed 
plasma groups and negative bands at 1007 cm-1, 1210 cm-1, 1260 cm-1, 1346 cm-1 1460 cm-1 and 
1660 cm-1 in the moderately haemolysed plasma group. The positive bands assigned to proteins, 
amino acids, carotenoids and lipids, and negative bands related to amino acids, proteins and lipids. 
The PCA showed proteins and lipids are the major discriminating features between the Raman 
spectra of plasma from non and mildly haemolysed versus moderately haemolysed patient groups. 
Similar discriminating features were also observed in the difference spectrum analysis of Raman 
spectra from non-haemolysed and haemolysed plasma groups. 
3.4.2. CLS fitting analysis 
 
CLS fitting analysis was performed to examine the alterations in the weighting of analytes in 
Raman and FTIR spectra with variable haemolysis. Significance testing was performed on the 
identified plasma analytes using two-tailed students t-tests with the significance level of p≤0.05, 
0.01 and 0.001. Figure 12 shows the results of CLS fitting analysis performed on the non-
haemolysed and haemolysed plasma second derivative FTIR spectra. In particular a differentiation 
in the weighting of albumin, phosphatidyl-ethanolamine (p-ethanolamine), uric acid, ceramide, 
thymidine, ubiquitin, triglyceride, Interleukin-6 and Interleukin-8 were observed between the 
FTIR spectra of non-haemolysed and haemolysed plasma samples. An increase in the weighting 
of albumin, ceramide, uric acid and ubiquitin was observed with an increase in haemolysis. 
Conversely a decreased weighting of thymidine and interleukin-6 was observed with increase in 
haemolysis. Similarly, a decreased weighting of triglyceride was observed in the haemolysed 
samples compared to non-haemolysed plasma samples. The increase in ceramide and p-
ethanolamine suggests an increase in lipid concentration with increase in haemolysis. An increased 
concentration of albumin [13] and ubiquitin [39] with an increase in haemolysis has also been 
reported previously. 
Figure 13 shows the results of CLS fitting analysis performed on the Raman spectra from non-
haemolysed and haemolysed plasma. Significant differences were observed in the weighting of 
uric acid, albumin, insulin, p-ethanolamine, creatinine, interleukin-6, RNA, urea and thymidine. 
A decreased weighting for uric acid and urea was observed with increase in haemolysis. A 
decreased concentration of uric acid with increase in haemolysis has also been reported previously 
[21] and may arise from a premature decomposition of haemoglobin [21]. Conversely an increased 
weighting of RNA and Interleukin-6 was observed with increase in haemolysis. Kirschner et al. 
reported an increase in the micro RNA levels in haemolysed plasma specimens [23]. The weighting 
of insulin within Raman spectra was decreased in mildly haemolysed samples and increased in 
moderately haemolysed plasma samples. The weighting of albumin and creatinine was decreased 
in moderately haemolysed samples compared to non and mildly haemolysed plasma samples. 
Variations in the weighting of albumin, uric acid, p-ethanolamine, interleukin-6 and thymidine 
were observed in both FTIR and Raman spectra of non-haemolysed and haemolysed plasma 
samples. Increased weighting of p-ethanolamine was observed in both FTIR and Raman spectral 
analysis. The FTIR spectral analysis showed an increased weighting of albumin with an increase 
in haemolysis but a slightly decreased level of albumin was observed in the Raman spectra of the 
moderately haemolysed plasma samples. A decreased weighting of uric acid, thymidine and 
interleukin-6 was observed in the FTIR spectral analysis with an increase in haemolysis. 
Conversely, an increased weighting of uric acid, thymidine and interleukin-6 levels were observed 
in the Raman spectral analysis. The differences in the CLS fitting analysis results of FTIR and 
Raman spectra may be due to the employment of different pre-processing and sample preparation 
methods. Second derivative FTIR spectra were used in this analysis, second derivative spectra 
allow more distinct identification of small and adjacent lying absorption peaks which are not 
clearly visible in the original spectrum. The FTIR spectra were recorded from diluted and dried 
plasma samples and Raman spectra were recorded from liquid plasma samples. Differences in the 
sample preparation methods might also affect the identification of plasma analytes. However, 
further studies would be required to confirm the variation in plasma analytes due to the different 
sample preparation methods. 
4. Interpatient variability 
The above studies were carried out on plasma samples obtained from various prostate cancer 
patients. To avoid any interpatient variability, plasma from a healthy control subject was spiked 
with increasing concentrations of diluted haemoglobin (extracted from whole blood), 0.44 g/L 
(mildly haemolysed), 0.93 g/L (moderately-haemolysed) and 1.31g/L (grossly-haemolysed). 
Figure 14 shows the mean spectra of non-haemolysed and in-vitro haemolysed plasma samples. 
Intensity related differences were observed across the spectra in the analysed plasma groups. A 
decrease in the bands around 1007 cm-1, 1450 cm-1 and 1660 cm-1 were observed with an increase 
in in-vitro haemolysis. These spectral features were increased with an increase in haemolysis in 
the Raman spectra of plasma from prostate cancer patients and could originate in in-vivo 
haemolysis or interpatient variability. Figure 15 shows the PCA scatter plot for non-haemolysed 
and in-vitro spiked-haemolysed plasma samples. The first two PC’s accounted for ∼25% of the 
total percentage variance and the scatter plot revealed overlapped clusters between the analysed 
groups. This suggests that there are no significant discriminating spectral features between the 
non-haemolysed and in-vitro haemolysed plasma specimens. 
The CLS fitting analysis performed on the in-vitro haemolysed plasma samples showed 
differences in the weighting of uric acid, albumin, insulin, p-ethanolamine, Interleukin-6, RNA, 
urea and thymidine (Figure 16). A decrease in insulin concentration was observed with an increase 
in haemolysis. This might be attributable to the previously observed release of proteolytic enzymes 
during hemolysis that destroys small peptides such as insulin, gastrin etc [22]. However, this trend 
was not observed in prostate cancer plasma samples. The increased concentration of urea in 
haemolysed samples was reported previously [40] and this effect might be due to the cellular 
release of urea into plasma during haemolysis [40]. However, in this study, the concentration of 
urea was increased gradually from non-haemolysed through mildly haemolysed up to moderately 
haemolysed samples and then decreased in grossly haemolysed plasma samples. Conversely, a 
decreased weighting of urea was observed in prostate cancer plasma samples with an increase in 
haemolysis. The decreased levels of uric acid [13], creatinine [13], insulin [22] and increased levels 
of urea [40], micro RNA [23] and interleukins [41] were reported with an increase in haemolysis. 
Similar trends were observed in this study up to moderately haemolysed samples but a deviation 
in this trend was observed in grossly haemolysed samples. This might be due to dilution or to 
interference from the bright red colour of haemoglobin as more haemoglobin was added to the 
plasma to produce the grossly haemolysed plasma sample. This results in dilution and alteration 
of analytes present in the plasma sample. Previous studies have also reported variations in severely 
haemolysed plasma samples due to dilution [13, 40]. 
 The weighting of uric acid, Interleukin-6 and RNA were consistent in both in-vitro haemolysed 
and prostate cancer plasma samples and the weighting of urea, insulin, p-ethanolamine, thymidine 
and creatine were inconsistent between the in-vitro and prostate cancer plasma samples. Consistent 
weighting of pure components in in-vitro haemolysed samples and prostate cancer haemolysed 
plasma samples suggests the interference of haemoglobin colour and intercellular components of 
RBC in the weighing of plasma analytes. Inconsistent weighting of pure components in in-vitro 
haemolysed and prostate cancer haemolysed plasma samples might be due to in-vivo haemolysis 
or due to the development of cancer.  
5. Conclusions 
 
Haemolysis, in-vitro or in-vivo, can affect the concentration of analytes present in the blood 
plasma and serum. Haemolysis can interfere in the quantification of several analytes in three 
different ways. The first one is the interference of the red coloration of haemoglobin with the 
absorption of light as it passes through a sample. The second interference is by releasing analytes 
into the serum or plasma that are in high concentration within the red blood cells and the third 
interference is by increasing lipid and fatty acid concentration in in-vivo haemolysis. Many studies 
have reported the interference of haemoglobin in various biochemical assays, including UV-visible 
spectroscopy. This study aimed to investigate the changes in the IR and Raman spectra of non-
haemolysed and haemolysed plasma samples. The mean spectra showed more changes in the FTIR 
spectral features of non-haemolysed and haemolysed patient plasma groups compared to the 
Raman spectral features. The increased haemolysis with an increase in the lipid content suggests 
an in-vivo haemolysis in the prostate cancer plasma samples. The PCA analysis performed on 
FTIR spectra showed a good separation of the plasma groups compared to the PCA performed on 
Raman spectra. This suggest that FTIR spectroscopy is a preferred method for the analysis of 
haemolysed samples. Finally, the CLS fitting analysis suggested significant alterations in the 
weighing of analytes in FTIR and Raman spectra of non-haemolysed and haemolysed patient 
plasma groups. The Raman spectroscopy study on in-vitro haemolysed samples showed minor 
changes in the spectral features of non-haemolysed and haemolysed plasma specimens and CLS 
fitting analysis showed similar changes in the weighting of some pure components as observed in 
the Raman spectra of plasma from prostate cancer patients.  
This study suggests that the FTIR spectra show more significant changes in the spectral features 
and in the weighting of pure components due to haemolysis compared to the Raman spectra. 
However, further FTIR studies should be performed on in-vitro haemolysed samples to confirm 
these results. Both in-vitro and in-vivo haemolysis is a common phenomenon and rejecting these 
samples could limit the diagnostic performance of Raman and FTIR spectroscopy. However, when 
including haemolysed samples in clinical spectroscopy studies, it is important to consider any 
changes in FTIR and Raman spectral features due to haemolysis when comparing results within 
and between experiments. Differences in the spectral features due to haemolysis will be observed 
within the patient group but most likely, these differences will be minor when compared between 
patient groups, for example control and cancer cases. However, further studies are needed to 
confirm this. 
This is the first study to report the effect of haemolysis on infrared and Raman spectra of blood 
plasma. This study was performed on a limited sample set and validation of these results on a 
larger cohort will be necessary to confirm the effect of in-vitro and in-vivo haemolysis on FTIR 
and Raman spectra of blood plasma. Future work should also involve biological assays showing 
proteins, lipids, circulating nucleic acids and other analyte levels to corroborate the findings of the 
CLS fitting analysis. 
Funding: This research was funded by an Irish Research Council Postgraduate Award, COST 
Action (BM1401) Short Term Scientific Mission Award, Irish Research Council-Ulysses Award 
(Grant Number PJ29007), EU FP7 Network of Excellence DoReMi (Grant Number 249689) and 
Science Foundation Ireland (11/RFP.1/BMT/3317). 
Acknowledgements: Cancer Trials Ireland acted as sponsor for the CTRIAL-IE (ICORG) 08-17 
study, providing project management, protocol development and monitoring, patient information 
leaflet and CRF development, ethics application and amendments. The authors are very grateful 
to the patients who participated in the CT-IE 08-17 study and donated blood samples for this 
translational research study. 
 






(1)  Lippi, G., Blanckaert, N., Bonini, P., Green, S., Kitchen, S., Palicka, V., Vassault, A. J., 
Plebani, M. Haemolysis: An Overview of the Leading Cause of Unsuitable Specimens in 
Clinical Laboratories. Clinical Chemistry and Laboratory Medicine. 2008, 46(6), 764-72. 
(2)  Thomas, K. L. Haemolysis as Influence and Interference Factor. J. Int. Fed. Clin. Chem. 
Lab. Med. 2002, 13 (4), 95–98. 
(3)  Carraro, P., Servidio, G., Plebani, M. Hemolyzed Specimens: A Reason for Refection of a 
Clinical Challenge? Clin Chem. 2000, 46 (2), 306–307. 
(4)  Rytting, M., Worth, L., Jaffe, N. Hemolytic Disorders Associated with Cancer. Hematol 
Oncol Clin North Am. 1996, 10 (2), 365–376. 
(5)  Go, R. S., Winters, J. L., Kay, N. E. How I Treat Autoimmune Hemolytic Anemia. Blood. 
2017, 129(22), 2971-2979. 
(6)  Vercaemst, L. Hemolysis in Cardiac Surgery Patients Undergoing Cardiopulmonary 
Bypass: A Review in Search of a Treatment Algorithm. J. Extra. Corpor. Technol. 2008, 
40(4), 257–267. 
(7)  Howanitz, P. J., Lehman, C. M., Jones, B. A., Meier, F. A., Horowitz, G. L. Practices for 
Identifying and Rejecting Hemolyzed Specimens Are Highly Variable in Clinical 
Laboratories. Arch. Pathol. Lab. Med. 2015, 139(8), 1014-9. 
(8)  Lippi, G., Cervellin, G., Favaloro, E.J., Plebani, M. In Vitro and In Vivo Hemolysis - An 
Unresolved Dispute in Laboratory Medicine; Germany: Walter de Gruyter GmbH, 2012. 
(9)  Shih, AW., Mcfarlane, A., Verhovsek, M. Haptoglobin Testing in Hemolysis: Measurement 
and Interpretation. Am. J. Hematol. 2014. 89(4), 443-7. 
(10)  Marchand, A., Galen, R. S., Van Lente, F. The Predictive Value of Serum Haptoglobin in 
Hemolytic Disease. JAMA. 1980, 243(19), 1909-11. 
(11)  Kormoczi, G.F., Saemann, M.D., Buchta, C., Peck-Radosavljevic, M., Mayr, W.R., 
Schwartz, D.W.M., Dunkler, D., Spitzauer, S., Panzer, S. Influence of Clinical Factors on 
the Haemolysis Marker Haptoglobin. Eur. J. Clin. Invest. 2006, 36(3), 202-9. 
(12)  Howanitz, P. J., Lehman, C. M., Jones, B. A., Meier, F. A., Horowitz, G. L. Clinical 
Laboratory Quality Practices When Hemolysis Occurs. Arch. Pathol. Lab. Med. 2015, 
139(7), 901-6. 
(13)  Koseoglu, M., Hur, A., Atay, A., Cuhadar, S. Effects of Hemolysis Interference on Routine 
Biochemistry Parameters. Biochem. Medica. 2011, 21(1), 79-85. 
(14)  Sahu, A., Sawant, S., Mamgain, H., Krishna, C. M. Raman Spectroscopy of Serum: An 
Exploratory Study for Detection of Oral Cancers. Analyst 2013, 138, 4161–4174.  
(15)  Blat, A.; Wiercigroch, E.; Smeda, M.; Wislocka, A.; Chlopicki, S.; Malek, K. Fourier 
Transform Infrared Spectroscopic Signature of Blood Plasma in the Progression of Breast 
Cancer with Simultaneous Metastasis to Lungs. J. Biophotonics 2019, 12(10), e201900067. 
(16)  González-Solís, J. L.; Martínez-Espinosa, J. C.; Torres-González, L. A.; Aguilar-Lemarroy, 
A.; Jave-Suárez, L. F.; Palomares-Anda, P. Cervical Cancer Detection Based on Serum 
Sample Raman Spectroscopy. Lasers Med. Sci. 2014, 29 (3), 979–985. 
(17)  Medipally, D. K. R.; Maguire, A.; Bryant, J.; Armstrong, J.; Dunne, M.; Finn, M.; Lyng, F. 
M.; Meade, A. D. Development of a High Throughput (HT) Raman Spectroscopy Method 
for Rapid Screening of Liquid Blood Plasma from Prostate Cancer Patients. Analyst 2017, 
142 (8), 1216–1226. 
(18)  Dinesh K.R. Medipally, Thi Nguyet Que Nguyen, Jane Bryant, Valérie Untereiner, Ganesh 
D. Sockalingum, Daniel Cullen, Emma Noone, Shirley Bradshaw, Marie Finn, Mary 
Dunne, Aoife M. Shannon, John Armstrong, F. M. L. and A. D. M. Monitoring 
Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR 
Spectroscopy of Liquid Biopsies. Cancers (Basel). 2019, 11 (7), 925. 
(19)  Helm, D.; Labischinski, H.; Naumann, D. Elaboration of a Procedure for Identification of 
Bacteria Using Fourier-Transform IR Spectral Libraries: A Stepwise Correlation Approach. 
J. Microbiol. Methods. 1991, 14(2), 127-142.  
(20)  Lacombe, C.; Untereiner, V.; Gobinet, C.; Zater, M.; Sockalingum, G. D.; Garnotel, R. 
Rapid Screening of Classic Galactosemia Patients: A Proof-of-Concept Study Using High-
Throughput FTIR Analysis of Plasma. Analyst 2015, 140 (7), 2280–2286.  
(21)  Yucel, D.; Dalva, K. Effect of in Vitro Hemolysis on 25 Common Biochemical Tests. Clin. 
Chem. 1992, 38(4), 575-7. 
(22)  Jones, A. M.; Honour, J. W. Unusual Results from Immunoassays and the Role of the 
Clinical Endocrinologist. Clin. Endocrinol. (Oxf). 2006, 64(3):234-44.  
(23)  Kirschner, M. B.; Edelman, J. J. B.; Kao, S. C. H.; Vallely, M. P.; Van Zandwijk, N.; Reid, 
G. The Impact of Hemolysis on Cell-Free MicroRNA Biomarkers. Front. Genet. 2013, 24, 
4, 94. 
(24)  Opus 5 Reference Manual; Bruker OPTIK GmbH, 2004. 
(25)  Savitzky, A.; Golay, M. J. E. Smoothing and Differentiation of Data by Simplified Least 
Squares Procedures. Anal. Chem. 1964, 36 (8), 1627-1639. 
(26)  Maguire, A.; Vegacarrascal, I.; White, L.; Mcclean, B.; Howe, O.; Lyng, F. M.; Meade, A. 
D. Analyses of Ionizing Radiation Effects In Vitro in Peripheral Blood Lymphocytes with 
Raman Spectroscopy. Radiat. Res. 2015, 183 (4), 407–416. 
(27)  Choquette SJ, Etz ES, Hurst WS, Blackburn DH, L. S. Relative Intensity Correction of 
Raman Spectrometers: NIST SRMs 2241 through 2243 for 785 Nm, 532 Nm, and 488 
Nm/514.5 Nm Excitation. Appl. Spectrosc. 2007, 61 (2), 117–129. 
(28)  Notingher, I.; Jell, G.; Notingher, P. L.; Bisson, I.; Polak, J. M. P.; Hench, L. L. Raman 
Spectroscopy: Potential Tool for in Situ Characterization of Bone Cell Differentiation. Key 
Eng. Mater. 2005, 284-286, 545-548. 
(29)  Wu, Y.; Dong, Y.; Jiang, J.; Li, H.; Zhu, T.; Chen, S. Evaluation of the Bone-Ligament and 
Tendon Insertions Based on Raman Spectrum and Its PCA and CLS Analysis. Sci. Rep. 
2017, 7, 38706. 
(30)  Stanimirovic, O.; Boelens, H. F. M.; Mank, A. J. G.; Hoefsloot, H. C. J.; Smilde, A. K. 
Profiling of Liquid Crystal Displays with Raman Spectroscopy: Preprocessing of Spectra. 
Appl. Spectrosc. 2005, 59(3), 267-74. 
(31)  Nikolac, N. Lipemia: Causes, Interference Mechanisms, Detection and Management. 
Biochemia Medica. 2014, 4(1), 57–67. 
(32)  Dimeski, G.; Mollee, P.; Carter, A. Increased Lipid Concentration Is Associated with 
Increased Hemolysis. Clinical Chemistry. 2005, 51(12), 2425. 
(33)  Staniszewska-Slezak, E.; Fedorowicz, A.; Kramkowski, K.; Leszczynska, A.; Chlopicki, S.; 
Baranska, M.; Malek, K. Plasma Biomarkers of Pulmonary Hypertension Identified by 
Fourier Transform Infrared Spectroscopy and Principal Component Analysis. Analyst. 
2015, 140(7), 2273-9. 
(34)  Bonnier, F.; Baker, M. J.; Byrne, H. J. Vibrational Spectroscopic Analysis of Body Fluids: 
Avoiding Molecular Contamination Using Centrifugal Filtration. Anal. Methods. 2014, 
6(14), 5155-5160.  
(35)  Maziak, D. E.; Do, M. T.; Shamji, F. M.; Sundaresan, S. R.; Perkins, D. G.; Wong, P. T. 
Fourier-Transform Infrared Spectroscopic Study of Characteristic Molecular Structure in 
Cancer Cells of Esophagus: An Exploratory Study. Cancer Detect. Prev. 2007, 31(3), 244-
53. 
(36)  Gonzalez-Solís, J. L.; Martínez-Espinosa, J. C.; Salgado-Román, J. M.; Palomares-Anda, 
P. Monitoring of Chemotherapy Leukemia Treatment Using Raman Spectroscopy and 
Principal Component Analysis. Lasers Med. Sci. 2014, 29(3), 1241-9. 
(37)  Movasaghi, Z.; Rehman, S.; Rehman, I. U. Raman Spectroscopy of Biological Tissues. 
Applied Spectroscopy Reviews. 2007, 42(5), 493-541.  
(38)  Borges, R. de C. F.; Navarro, R. S.; Giana, H. E.; Tavares, F. G.; Fernandes, A. B.; Silveira, 
L. Detecting Alterations of Glucose and Lipid Components in Human Serum by Near-
Infrared Raman Spectroscopy. Rev. Bras. Eng. Biomed. 2015, 31(2), 160-168.  
(39)  Takada, K.; Nasu, H.; Hibi, N.; Tsukada, Y.; Shibasaki, T.; Fujise, K.; Fujimuro, M.; 
Sawada, H.; Yokosawa, H.; Ohkawa, K. Serum Concentrations of Free Ubiquitin and 
Multiubiquitin Chains. Clin. Chem. 1997, 43(7), 1188-95. 
(40)  Lippi, G.; Salvagno, G. L.; Montagnana, M.; Brocco, G.; Guidi, G. C. Influence of 
Hemolysis on Routine Clinical Chemistry Testing. Clin. Chem. Lab. Med. 2006, 44(3), 311-
6. 
(41)  Wei, J.; Zhao, J.; Schrott, V.; Zhang, Y.; Gladwin, M.; Bullock, G.; Zhao, Y. Red Blood 
Cells Store and Release Interleukin-33. J. Investig. Med. 2015. 63(6), 806-10. 





























Table 1: Factors causing in vitro haemolysis [2]. 
During specimen collection After Specimen collection 
Strong aspiration while puncturing superficial 
veins 
Vigorous shaking of collected sample 
Aspiration with large needles causes higher 
haemolysis because of an increase in the flow-
rate, flow speed and turbulence. 
Centrifugation of sample before completion of 
coagulation 
Partial blockage of a venous or arterial catheter 
causes strong aspiration of the sample collected 
with a syringe. 
Centrifugation of partially coagulated samples 
from patients on anticoagulants 
Specimen collection and subsequent splitting 
into multiple tubes with a syringe. 
Positive or negative pressure in sample 
collection tube 
 Dilution of blood with hypotonic solutions 
 Freeze thawing of whole blood 
 Storage or transportation of collected specimen 
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Table 3: Pure molecular reference species used in haemolysis study 
Category Pure components  
Protein and related 
compounds 
Apolipoprotein E4, Albumin, Haemoglobin 
Interleukin-6, Interleukin-8 and Ubiquitin 
 
Lipids and Fatty acids 
Arachidonic acid, Cholesterol, Ceramide 
Linolenic acid, Linoleic acid, 




phosphatidylserine, prostaglandin E1, 
phosphatidylinositol 
 
Nucleic acids and 
related compounds DNA, RNA, Thymidine 
 
Metabolism and others 
Glucose, Glycogen, Creatinine, Uric acid, Urea, 













Figures      
                                            
           
Figure 1: Mean and standard deviation of instrument response corrected and pre-processed liquid 
plasma Raman spectrum. 
                      
 
Figure 2: Three different types of liquid plasma samples in plasma biobank. 
 
 
   Figure 3: UV-VIS absorption spectrum of oxyhaemoglobin 
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Figure 5: Mean and standard deviation Raman spectrum of (A) haemoglobin standard (B) diluted 
haemoglobin standard and (C) haemoglobin isolated from blood.  
 











      
 
                      
Figure 7: Difference FTIR spectra of non-haemolysed and haemolysed plasma groups. Difference 
spectra were computed by subtracting the mean FTIR spectra of haemolysed plasma from the mean 







                
Figure 8: Mean Raman spectra of non-haemolysed, mildly-haemolysed and moderately-













                     
Figure 9: Difference Raman spectra of non-haemolysed and haemolysed plasma groups. 
Difference spectra were computed by subtracting the mean Raman spectra of haemolysed plasma 











B.    
         
Figure 10: PCA for FTIR spectra of non-haemolysed, mildly-haemolysed and moderately-
haemolysed plasma samples. (A) Score plots are shown for patients at non-haemolysed plasma 
(blue), mildly-hemolysed plasma (red), and moderately-hemolysed plasma (yellow (B) PC-1 and 
PC-2 loading plots for regions 800 – 1800 cm-1 and 2800 – 3100 cm-1. Covariance ellipse (95% 
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Figure 11: PCA for Raman spectra of non-haemolysed, mildly-haemolysed and moderately-
haemolysed plasma samples. (A) Score plots are shown for patients at non-haemolysed plasma 
(blue), mildly-hemolysed plasma (red), and moderately-hemolysed plasma (yellow (B) PC-1 and 
PC-2 loading plots for regions 600 – 1800 cm-1. Covariance ellipse (95% confidence) are shown 
for each class. 
 
Figure 12: Relative concentrations of pure molecular reference species from least squares fit of 
FTIR spectra of non-haemolysed and haemolysed prostate cancer plasma samples. Error bars 
represent the standard error. Significance shown by (*, **, and ***) indicates the significance of 
p≤0.05, p≤0.01 and p≤0.001 respectively. 
 
Figure 13: Relative concentrations of pure molecular reference species from least squares fit of 
Raman spectra of non-haemolysed and haemolysed prostate cancer plasma samples. Error bars 
represent the standard error. Significance shown by (*, **, and ***) indicates the significance of 

















Figure 15: PCA scatter plot for Raman spectra of non-haemolysed and in vitro haemolysed plasma 





Figure 16: Relative concentrations of pure molecular reference species from least squares fit of 
Raman spectra of non-haemolysed and in vitro haemolysed plasma samples. Error bars represent 
the standard error. Significance shown by (*, **, and ***) indicates the significance of p≤0.05, 












Table S1: Details of pure molecular reference species used in this study. 
 
SN Component name Company Product number State 
Protein and related species 
1 Albumin Sigma Aldrich A7030 Powder 
2 Haemoglobin Sigma Aldrich H7379 Powder 
3 Interleukin-6 Sigma Aldrich I13965 Powder 
4 Interleukin-8 Sigma Aldrich I-1645 Powder 
5 Ubiquitin Sigma Aldrich U6253 Powder 
6 Apolipoprotein E4 Sigma Aldrich A3234 Powder 
Nucleic acids and nucleobases 
7 RNA Sigma Aldrich R6750 Powder 
8 DNA Sigma Aldrich D-1626 Powder 
9 Thymidine Sigma Aldrich T1895 Powder 
Lipids, fatty acids and related species 
10 Ceramide Sigma Aldrich 22244 Powder 
11 Cholesterol Sigma Aldrich C3045 Powder 
12 Linoleic acid Sigma Aldrich L1376 Liquid 
13 Linolenic acid Sigma Aldrich L2376 Liquid 
14 Oleic acid Sigma Aldrich O1008 Liquid 
15 L-α-Phosphatidylcholine Sigma Aldrich L4129 Powder 
16 L-α-Phosphatidylserine Avanti 8703363C Liquid 
17 L-α-Phosphatidylinositol Sigma Aldrich P-6636 Powder 
18 L-α-Phosphatidylethanolamine Sigma Aldrich P-7693 Powder 
19 Prostaglandin E1 Sigma Aldrich P5515 Liquid 
20 PUFA SUPELCO 47015-U Liquid 
21 Sphingomyelin Sigma Aldrich S0756 Powder 
22 Triglyceride mixture Sigma Aldrich 17811-1AMP Powder 
23 Arachidonic acid Sigma Aldrich 10931 Liquid 
 
Other metabolites 
24 β-Carotene Sigma Aldrich C4582 Powder 
25 Urea Sigma Aldrich U4884 Powder 
26 Uric acid Sigma Aldrich U2625 Powder 
27 Creatinine Sigma Aldrich C4255 Powder 
28 Glucose Sigma Aldrich G8270 Powder 
29 Glycogen Sigma Aldrich G0885 Powder 























































































































































                                  
                                 

































































































































                                 
                                      
 
 
 
 
 
 
 
 
 
